Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc (A) delivers cutting-edge analytical instruments and laboratory solutions for scientific advancement across biopharmaceutical, diagnostic, and environmental sectors. This page provides investors and industry professionals with a centralized source for all official company announcements and market-relevant developments.
Access real-time updates on Agilent's financial performance, strategic partnerships, product innovations, and regulatory milestones. Our curated news collection includes earnings releases, executive leadership updates, R&D breakthroughs, and industry event coverage—all essential for tracking the company's impact on life sciences and laboratory technology.
Key focus areas include advancements in genomic research tools, sustainability initiatives in lab operations, and cross-sector collaborations driving scientific discovery. Bookmark this page to stay informed about Agilent's evolving role in enabling precision medicine, environmental testing, and next-generation materials analysis.
Agilent Technologies (NYSE: A) has announced its participation at the AACR Annual Meeting 2025 in Chicago, showcasing innovative cancer research solutions. The company unveiled three new Avida DNA Cancer Panels for ultra-sensitive detection of cancer genomic alterations from liquid biopsies, featuring a streamlined 5-hour workflow.
Key highlights include partnerships with Tagomics for their Interlace Multiomics assay integration with Agilent's SureSelect Cancer CGP assay, and collaboration with Roswell Park Cancer Center for the SureSelect Cancer Pan Heme Assay. Additionally, Agilent announced a strategic partnership with Abcam for IHC Companion Diagnostics development using Abcam's portfolio of over 10,000 recombinant monoclonal antibodies.
Agilent Technologies (NYSE: A) has received European IVDR certification for its PD-L1 IHC 22C3 pharmDx assay as a Companion Diagnostic (CDx) for gastric or gastroesophageal junction (GEJ) adenocarcinoma patients. The certification aids in identifying patients eligible for KEYTRUDA® therapy.
The assay is now IVDR certified for seven cancer indications, including non-small cell lung cancer, urothelial carcinoma, esophageal cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and cervical cancer. It remains the only IVDR-certified CDx for gastric and GEJ adenocarcinoma patients seeking KEYTRUDA treatment.
This expansion is particularly significant given that gastric cancer affected over 130,000 Europeans in 2022, with a 5-year survival rate of 26% in Europe. The assay works exclusively with Agilent's Autostainer Link 48 advanced staining solution.
Agilent Technologies (NYSE: A) has scheduled the release of its second-quarter fiscal year 2025 financial results after market close on Wednesday, May 28. The company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. Investors can access the listen-only webcast through the Events section of Agilent's investor relations website, where a recording will remain available for 90 days.
Agilent Technologies (NYSE: A) has announced its contribution to the FDA approval of AUCATZYL®, a CAR T therapy developed by Autolus Therapeutics. The company's xCELLigence Real-Time Cell Analysis (RTCA) technology played a important role in developing and validating the therapy's potency assay.
The xCELLigence RTCA platform provides continuous, real-time monitoring of cell behavior without labels or dyes, using electrical impedance to measure cell numbers, viability, and morphology. This technology offers advantages over traditional endpoint assays by enabling more accurate and timely decision-making in drug development.
Agilent and Autolus will present their findings at the 2025 Hybrid US Bioassay Conference in Tucson, Arizona, discussing lessons learned in CAR T Cell Product Potency Measurement.
Agilent Technologies (NYSE: A) will showcase its digital pathology solutions at the USCAP Conference in Boston, March 22-27, 2025. The company has developed an end-to-end digital pathology workflow in collaboration with Hamamatsu, PathAI, Proscia, and Visiopharm, integrating AI-driven precision pathology software with automated staining solutions.
The showcase will feature live demonstrations of scanning, image management, and AI-driven image analysis capabilities. Key products to be displayed include the Magnis NGS Prep System and NovoCyte Opteon Spectral Flow Cytometer.
Two symposiums are scheduled for March 24: a Digital Pathology Symposium on innovations and insights (12:00-1:00 PM ET) and a Medical Affairs Symposium focusing on PD-L1 Heterogeneity (5:30-7:00 PM ET).
Agilent Technologies (NYSE: A) has announced its participation in the USCAP Conference from March 22-27, 2025, in Boston, where it will showcase advanced digital pathology solutions. The company has developed an end-to-end digital pathology workflow in collaboration with Hamamatsu, PathAI, Proscia, and Visiopharm.
The integrated solution combines AI-driven precision pathology software with automated staining solutions, covering processes from tissue sample scanning to image analysis and data management. Key products to be showcased include the Magnis NGS Prep System and NovoCyte Opteon Spectral Flow Cytometer.
Two significant symposiums are scheduled for March 24: a Digital Pathology Symposium (12:00-1:00 PM ET) featuring experts from various institutions, and a Medical Affairs Symposium on PD-L1 Heterogeneity (5:30-7:00 PM ET). Visitors can explore these innovations at Agilent booth #512.
Agilent Technologies (NYSE: A) has awarded Columbia University an Agilent Research Catalyst (ARC) Award for Dr. Pawel Muranski's groundbreaking work in cellular immunotherapy. Dr. Muranski, Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center, is developing a novel cGMP platform for generating clinical-grade multi-specific CD4+ cytotoxic T cells to treat various cancers.
The award includes research funding and advanced Agilent instruments including a Seahorse XF Pro Analyzer, xCELLigence RTCA MP instrument, NovoCyte Penteon Flow Cytometer, BioTek Cytation 1 Cell Imaging Reader, and BioTek 800 TS Absorbance Reader. These tools will help accelerate the development of innovative manufacturing methods and establish standardized quality control assays for anti-cancer T cell production.
Agilent Technologies (NYSE: A) has received EU IVDR certification for two new companion diagnostic indications for its PD-L1 IHC 28-8 pharmDx kit, bringing the total European indications to nine. The approvals expand treatment eligibility for:
1. Early-stage non-small cell lung cancer (NSCLC) patients with PD-L1 expression ≥1% at high recurrence risk, enabling treatment with OPDIVO® plus platinum-based chemotherapy
2. Previously untreated advanced melanoma patients (12+ years) with tumor cell PD-L1 expression <1%, enabling treatment with Opdualag™
The kit, exclusively used with Agilent's Autostainer Link 48, addresses significant healthcare concerns: lung cancer (2+ million new cases, 1.77 million deaths annually) and melanoma (324,000+ new cases, 57,000+ deaths annually). As the only clinically validated test for these treatments, it aids pathologists and oncologists in treatment selection.
Agilent Technologies (NYSE: A) has announced its participation in TD Cowen's 45th Annual Health Care Conference. CEO Padraig McDonnell and CFO Bob McMahon will engage in a fireside chat scheduled for March 4, 2025, from 9:50-10:20 a.m. Eastern in Boston, Massachusetts.
The company will provide a live audio webcast of the presentation, which will also be available for replay through the Agilent Investor Relations website.
Agilent Technologies (NYSE: A) reported Q1 FY2025 results with revenue of $1.68 billion, showing growth of 1.4% reported and 1.2% core compared to Q1 2024. GAAP net income was $318 million ($1.11 per share), down from $348 million ($1.18 per share) in Q1 2024. Non-GAAP net income was $377 million ($1.31 per share), compared to $380 million ($1.29 per share) year-over-year.
By segment, Life Sciences and Diagnostics Markets Group revenue grew 4% reported to $647 million, Agilent CrossLab Group increased 1% to $696 million, while Applied Markets Group declined 4% to $338 million.
For FY2025, Agilent projects revenue of $6.68-6.76 billion (2.6-3.8% growth) and non-GAAP EPS of $5.54-5.61. Q2 outlook expects revenue of $1.61-1.65 billion with non-GAAP EPS of $1.25-1.28.
